Leerink Partners Reiterates Buy Rating on MoonLake Immunotherapeutics
Leerink Partners maintains its buy rating for MoonLake Immunotherapeutics with a $29 price target, a 48.95% upside from the current price.
Key Points
- Leerink Partners reiterated its buy rating on MoonLake Immunotherapeutics, setting a $29 price target on July 1, 2026.
- Leerink Partners's $29 price target implies 48.95% upside from MoonLake Immunotherapeutics's ($MLTX) current $19.47 share price.
- MoonLake shares were trading at $19.47 on Wednesday, with a market cap of approximately $1.63 billion.
- Several insiders, including CFO Matthias Bodenstedt, executed planned sales in June, while analyst consensus remains positive.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On July 1, 2026, Leerink Partners reiterated its buy rating on MoonLake Immunotherapeutics, listed on the NasdaqCM under the ticker MLTX. Analyst Thomas Smith set a price target of $29, reflecting confidence in the company's future prospects.
Leerink Partners vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
MoonLake Immunotherapeutics Stock Up 29.9%
Shares of NasdaqCM:MLTX traded near $19.47 on Wednesday. MoonLake Immunotherapeutics, a clinical-stage biotechnology company, has a market cap of about $1.63 billion. The company is not currently profitable, so it has no meaningful P/E ratio. Its stock has seen a 52-week low of $5.95 and a high of $62.75. The 50-day moving average is $18.15, while the 200-day moving average stands at $17.68. The company maintains a strong liquidity position with a current ratio of 8.60 and a quick ratio of 7.89, alongside a debt-to-equity ratio of 39.68.
$MLTX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at MoonLake Immunotherapeutics
Recent insider activity at MoonLake Immunotherapeutics included planned sales by Chief Financial Officer Matthias Bodenstedt, who sold 39,120 shares at an average price of $22.04 on June 22, 2026. Earlier in June, Bodenstedt also sold 2,794 shares at $19.60. Meanwhile, on June 17, several insiders, including BVF Partners, executed unplanned purchases, each acquiring 22,195 shares.
Analysts Set New Price Targets
On July 1, 2026, Leerink Partners maintained its buy rating on MoonLake Immunotherapeutics with a $29 price target. This is part of a broader positive analyst sentiment, as Needham also maintained a buy rating with a $30 target on May 12, 2026. HC Wainwright & Co. has been particularly optimistic, setting a $45 target on May 11, 2026. The overall analyst consensus remains a buy, with an average target price of about $27.62 based on 13 analyst opinions.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a biotechnology company based in Zug, Switzerland. It focuses on developing therapies for inflammatory skin and joint diseases. The company is working on Sonelokimab, a novel treatment targeting inflammatory diseases like hidradenitis suppurativa and psoriatic arthritis. Founded in 2021, MoonLake is led by CEO Dr. Jorge Santos da Silva and has about 130 employees.
Bottom Line
Leerink Partners' reiteration of a buy rating for MoonLake Immunotherapeutics reflects strong analyst confidence in the company's growth potential. While the stock has experienced volatility, trading near $19.47, its strong liquidity and innovative pipeline continue to attract interest. Investors should note that analyst ratings are based on historical data and may not reflect current market conditions.
Get MoonLake Immunotherapeutics alerts
New 13F filings, insider trades, and analyst moves on $MLTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.